Yes
Newer treatments for genotype 1 do not use peginterferon or ribavirin. A combination of sofosbuvir and simeprevir or a single pill containing ledipasvir and sofosbuvir can be used to treat hepatitis C in people who have genotype 1. If blood tests show that you have responded to antiviral therapy (the virus is not detected in your blood) after 6 months, treatment may be: Gilead reports that the majority of patients can be cured with a once-daily pill in a period of 8 to 12 weeks. Harvoni’s efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection.  1 Hepatitis C is a liver disease caused by the hepatitis C virus: the virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. 1 The hepatitis C virus is a bloodborne virus and the most common modes of infection are through unsafe injection practices; inadequate sterilization of medical equipment; and the transfusion of unscreened blood and blood products. 2  130–150 million people globally have chronic hepatitis C infection. Hepatitis C Virus Genotypes. An important variable for all patients with chronic hepatitis C virus (HCV) is the genotype of HCV with which they are infected. This is the strain of the virus to which they were exposed when they were infected, often many years prior to their evaluation, and it is determined by a simple blood test. Clinical Significance of Hepatitis C Genotypes. Genotype generally has not been found in epidemiological studies to play a large role in liver disease progression due to HCV. Rather, genotype is of clinical importance principally as a factor in response to HCV treatments. Most persons with chronic HCV infection are asymptomatic. However, many have chronic liver disease, which can range from mild to severe, including cirrhosis and liver cancer. Chronic liver disease in HCV-infected persons is usually insidious, progressing slowly without any signs or symptoms for several decades. Treatment for acute hepatitis C is similar to treatment for chronic hepatitis C. This issue was addressed in the 2009 AASLD Practice Guidance, the response rate to treatment is higher among persons with acute than with chronic HCV infection. Harvoni is the third drug approved by the FDA in the past year to treat chronic HCV infection. The FDA approved Olysio (simeprevir) in November 2013 and Sovaldi in December 2013. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with HCV have no symptoms of the disease until liver damage becomes apparent, which may take decades.  Six major strains (genotypes) of the hepatitis C virus (HCV) cause infection. You may be infected with more than one genotype at a time. 1  Genotype 1 is the most common strain in the United States. 2  Genotypes 1, 2, and 3 are found worldwide. 3  Genotype 4 is found throughout northern Africa. A combination of sofosbuvir and simeprevir or a single pill containing ledipasvir and sofosbuvir can be used to treat hepatitis C in people who have genotype 1. If blood tests show that you have responded to antiviral therapy (the virus is not detected in your blood) after 6 months, treatment may be: Yes. Prior infection with HCV does not protect against later infection with the same or different genotypes of the virus. This is because persons infected with HCV typically have an ineffective immune response due to changes in the virus during infection. Treatment for acute hepatitis C is similar to treatment for chronic hepatitis C. This issue was addressed in the 2009 AASLD Practice Guidance, the response rate to treatment is higher among persons with acute than with chronic HCV HCV Genotype: In the United States, approximately 70% of chronic HCV infections are caused byhepatitis C genotype 1, 15 to 20% by genotype 2, 10 to 12% genotype 3, 1% genotype 4, and lessthan 1% genotype 5 or 6. their HCV infection. HCV Genotype: In the United States, approximately 70% of chronic HCV infections are caused by. hepatitis C genotype 1, 15 to 20% by genotype 2, 10 to 12% genotype 3, 1% genotype 4, and less. than 1% genotype 5 or 6.
http://www.webmd.com/hepatitis/tc/hepatitis-c-genotypes-topic-overview http://www.hepatitispharmacy.com/ http://www.who.int/mediacentre/factsheets/fs164/en/ http://www.hepatitis.va.gov/provider/reviews/genotypes.asp http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm http://www.webmd.com/hepatitis/tc/hepatitis-c-genotypes-topic-overview http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm http://www.hepatitisc.uw.edu/pdf/screening-diagnosis/epidemiology-us/core-concept/all
can you have numerous genotype hcv infections